SG11201706293XA - Tau antisense oligomers and uses thereof - Google Patents
Tau antisense oligomers and uses thereofInfo
- Publication number
- SG11201706293XA SG11201706293XA SG11201706293XA SG11201706293XA SG11201706293XA SG 11201706293X A SG11201706293X A SG 11201706293XA SG 11201706293X A SG11201706293X A SG 11201706293XA SG 11201706293X A SG11201706293X A SG 11201706293XA SG 11201706293X A SG11201706293X A SG 11201706293XA
- Authority
- SG
- Singapore
- Prior art keywords
- antisense oligomers
- tau antisense
- tau
- oligomers
- antisense
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112058P | 2015-02-04 | 2015-02-04 | |
| US201562156684P | 2015-05-04 | 2015-05-04 | |
| US201562237922P | 2015-10-06 | 2015-10-06 | |
| US201562238941P | 2015-10-08 | 2015-10-08 | |
| US201662279612P | 2016-01-15 | 2016-01-15 | |
| US201662279610P | 2016-01-15 | 2016-01-15 | |
| US201662279614P | 2016-01-15 | 2016-01-15 | |
| PCT/US2016/016646 WO2016126995A1 (en) | 2015-02-04 | 2016-02-04 | Tau antisense oligomers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706293XA true SG11201706293XA (en) | 2017-09-28 |
Family
ID=55443327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706293XA SG11201706293XA (en) | 2015-02-04 | 2016-02-04 | Tau antisense oligomers and uses thereof |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11077132B2 (en) |
| EP (2) | EP3653712B1 (en) |
| JP (1) | JP2018505676A (en) |
| KR (1) | KR20180016970A (en) |
| CN (1) | CN107922946A (en) |
| AU (1) | AU2016215155A1 (en) |
| BR (1) | BR112017016663A2 (en) |
| CA (1) | CA2975525A1 (en) |
| CL (1) | CL2017001956A1 (en) |
| CO (1) | CO2017009008A2 (en) |
| CR (1) | CR20170359A (en) |
| DK (1) | DK3253875T3 (en) |
| HK (1) | HK1248276A1 (en) |
| IL (1) | IL253730A0 (en) |
| MA (1) | MA41586A (en) |
| MX (1) | MX2017010066A (en) |
| PE (1) | PE20171766A1 (en) |
| PH (1) | PH12017550069A1 (en) |
| RU (1) | RU2017127609A (en) |
| SG (1) | SG11201706293XA (en) |
| TW (1) | TW201641691A (en) |
| UY (1) | UY36550A (en) |
| WO (1) | WO2016126995A1 (en) |
| ZA (1) | ZA201705119B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101885383B1 (en) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | Novel nucleic acid prodrugs and methods of use thereof |
| US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| EP2831232A4 (en) | 2012-03-30 | 2015-11-04 | Univ Washington | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| TWI657819B (en) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | Compositions for modulating tau expression |
| JP6772156B2 (en) | 2015-02-04 | 2020-10-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | How to choose a therapeutic molecule |
| JOP20200228A1 (en) * | 2015-12-21 | 2017-06-16 | Novartis Ag | Compositions and methods for decreasing tau expression |
| JOP20190065A1 (en) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing tau expression |
| KR102674612B1 (en) * | 2016-12-01 | 2024-06-14 | 상가모 테라퓨틱스, 인코포레이티드 | Tau modulators and methods and compositions for their delivery |
| BR112020014011A2 (en) * | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | ANTISENSE OLIGONUCLEOTIDS DIRECTED TO ALPHA-SYNUCLEIN AND USES OF THE SAME |
| EP3749766A1 (en) | 2018-02-09 | 2020-12-16 | F.Hoffmann-La Roche Ag | Oligonucleotides for modulating tmem106b expression |
| EP3752612A4 (en) | 2018-02-12 | 2021-11-10 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| AU2019233612A1 (en) * | 2018-03-13 | 2020-09-10 | Janssen Pharmaceutica Nv | Modified oligonucleotides for use in treatment of tauopathies |
| CA3096682A1 (en) | 2018-04-13 | 2019-10-17 | Bristol-Myers Squibb Company | Novel phosphorous (v)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (v) compounds |
| EP3802824A1 (en) | 2018-06-05 | 2021-04-14 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating atxn2 expression |
| NZ770352A (en) * | 2018-07-03 | 2024-07-05 | Hoffmann La Roche | Oligonucleotides for modulating tau expression |
| EA202192733A1 (en) * | 2019-04-03 | 2022-03-14 | Бристол-Маерс Сквибб Компани | ANGPTL2 ANTISENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS |
| WO2020201339A1 (en) | 2019-04-04 | 2020-10-08 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating atxn2 expression |
| US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
| JP7155302B2 (en) | 2019-06-06 | 2022-10-18 | エフ．ホフマン－ラ ロシュ アーゲー | Antisense oligonucleotides targeting ATXN3 |
| JOP20220061A1 (en) * | 2019-09-17 | 2023-01-30 | Zynerba Pharmaceuticals Inc | Treatment of behavioral impairment in developmental and epileptic encephalopathy |
| WO2021249993A1 (en) | 2020-06-09 | 2021-12-16 | Roche Innovation Center Copenhagen A/S | Guanosine analogues for use in therapeutic polynucleotides |
| AR124229A1 (en) | 2020-12-03 | 2023-03-01 | Hoffmann La Roche | ANTISENSE OLIGONUCLOTIDES ACTING ON ATXN3 |
| US20230060373A1 (en) | 2020-12-03 | 2023-03-02 | Hoffmann-La Roche Inc. | Antisense Oligonucleotides Targeting ATXN3 |
| US20220195437A1 (en) * | 2020-12-11 | 2022-06-23 | Eisai R&D Management Co., Ltd. | Tau-targeting oligonucleotide gapmers |
| JP2024506709A (en) * | 2021-02-17 | 2024-02-14 | キュー－ステート バイオサイエンシーズ， インコーポレイテッド | UBE3A antisense therapeutic agent |
| EP4363576A1 (en) * | 2021-06-29 | 2024-05-08 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides |
| AU2023267136A1 (en) * | 2022-05-13 | 2024-10-10 | Julius-Maximilians-Universität Würzburg | Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
| US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5166195A (en) * | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
| US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| EP0580751A1 (en) | 1991-04-19 | 1994-02-02 | Schering Corporation | Subunit of the human interleukin-3 receptor |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| DK0848755T4 (en) | 1995-09-08 | 2011-05-23 | Genentech Inc | VEGF related protein |
| IL127558A0 (en) | 1996-07-03 | 1999-10-28 | Genentech Inc | Hepatocyte growth factor receptor agonists and uses thereof |
| US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
| GB9812127D0 (en) | 1998-06-06 | 1998-08-05 | Univ Glasgow | Detection of neural activity |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| ATE407949T1 (en) | 1998-12-30 | 2008-09-15 | Beth Israel Hospital | CHARACTERIZATION OF THE PROTEIN FAMILY OF SOC/CRAC CALCIUM CHANNELS |
| EP1141014B1 (en) | 1999-01-06 | 2004-12-08 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variant |
| DE60042550D1 (en) | 1999-01-06 | 2009-08-27 | Genentech Inc | MUTED VARIANTS OF THE INSULIN-SIMILAR GROWTH FACTOR I (IGF-I) |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| DK1521831T3 (en) * | 2002-07-12 | 2008-06-30 | Axon Neuroscience | Transgenic animals expressing truncated Alzheimer's tau protein |
| EP2284269B1 (en) * | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| AU2004209599A1 (en) | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
| US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
| AU2005286738A1 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| DE602007009487D1 (en) | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGUE |
| US20090292006A1 (en) | 2006-05-05 | 2009-11-26 | Sanjay Bhanot | Compounds and methods for modulating expression of dgat2 |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| EP2410054B2 (en) | 2006-10-18 | 2019-12-11 | Ionis Pharmaceuticals, Inc. | Antisense compounds |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| ES2386492T3 (en) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| WO2009100320A2 (en) | 2008-02-07 | 2009-08-13 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| EP2274423A2 (en) | 2008-04-04 | 2011-01-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
| US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
| WO2010036698A1 (en) | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| CN101812127B (en) * | 2009-02-19 | 2013-03-06 | 中国科学技术大学 | Microtubule-associated protein and coding genes and application thereof |
| US20100275274A1 (en) * | 2009-04-28 | 2010-10-28 | National Yang-Ming University | Mouse model for depression, schizophrenia and alzheimer's disease |
| EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
| WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US9193752B2 (en) | 2010-03-17 | 2015-11-24 | Isis Pharmaceuticals, Inc. | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2561340B1 (en) | 2010-04-21 | 2019-01-23 | Vanderlande APC Inc. | Method and system for use in performing security screening |
| WO2012109395A1 (en) | 2011-02-08 | 2012-08-16 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US8778884B2 (en) | 2011-05-26 | 2014-07-15 | Fondazione Salvatore Maugeri Clinica del Lavora e Della Riabilitazione | Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto |
| US9243291B1 (en) | 2011-12-01 | 2016-01-26 | Isis Pharmaceuticals, Inc. | Methods of predicting toxicity |
| EP2831232A4 (en) * | 2012-03-30 | 2015-11-04 | Univ Washington | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| EP3336189A1 (en) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| EP2906255B1 (en) | 2012-10-12 | 2023-02-22 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
| JP6243919B2 (en) * | 2012-10-24 | 2017-12-06 | フラウンホーファ−ゲゼルシャフト ツァー フォルデルング デア アンゲバンデン フォルシュンク エー． ファオ．Ｆｒａｕｎｈｏｆｅｒ−Ｇｅｓｅｌｌｓｃｈａｆｔ Ｚｕｒ Ｆｏｒｄｅｒｕｎｇ Ｄｅｒ Ａｎｇｅｗａｎｄｔｅｎ Ｆｏｒｓｃｈｕｎｇ Ｅ． Ｖ． | Microtubule-modifying compound |
| US9014359B1 (en) | 2013-01-11 | 2015-04-21 | Time Warner Cable Enterprises Llc | Generation of phone number lists and call filtering |
| AU2014236156C1 (en) | 2013-03-14 | 2020-12-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Tau expression |
| EP3019175B1 (en) | 2013-07-11 | 2019-12-04 | The Trustees of Columbia University in the City of New York | Micrornas that silence tau expression |
| TWI657819B (en) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | Compositions for modulating tau expression |
| WO2016019063A1 (en) | 2014-07-29 | 2016-02-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression |
| JP6350987B2 (en) | 2014-08-04 | 2018-07-04 | 本田技研工業株式会社 | Thermostable β-xylosidase belonging to GH family 3 |
-
2016
- 2016-02-04 EP EP19214990.4A patent/EP3653712B1/en active Active
- 2016-02-04 AU AU2016215155A patent/AU2016215155A1/en not_active Abandoned
- 2016-02-04 DK DK16706943.4T patent/DK3253875T3/en active
- 2016-02-04 MA MA041586A patent/MA41586A/en unknown
- 2016-02-04 SG SG11201706293XA patent/SG11201706293XA/en unknown
- 2016-02-04 EP EP16706943.4A patent/EP3253875B1/en active Active
- 2016-02-04 MX MX2017010066A patent/MX2017010066A/en unknown
- 2016-02-04 US US15/549,021 patent/US11077132B2/en active Active
- 2016-02-04 PE PE2017001323A patent/PE20171766A1/en unknown
- 2016-02-04 US US15/016,169 patent/US10799523B2/en active Active
- 2016-02-04 CR CR20170359A patent/CR20170359A/en unknown
- 2016-02-04 KR KR1020177024109A patent/KR20180016970A/en unknown
- 2016-02-04 UY UY0001036550A patent/UY36550A/en unknown
- 2016-02-04 CN CN201680019681.3A patent/CN107922946A/en active Pending
- 2016-02-04 JP JP2017541089A patent/JP2018505676A/en active Pending
- 2016-02-04 RU RU2017127609A patent/RU2017127609A/en not_active Application Discontinuation
- 2016-02-04 CA CA2975525A patent/CA2975525A1/en not_active Abandoned
- 2016-02-04 TW TW105103800A patent/TW201641691A/en unknown
- 2016-02-04 BR BR112017016663A patent/BR112017016663A2/en not_active Application Discontinuation
- 2016-02-04 WO PCT/US2016/016646 patent/WO2016126995A1/en active Application Filing
-
2017
- 2017-07-27 ZA ZA2017/05119A patent/ZA201705119B/en unknown
- 2017-07-30 IL IL253730A patent/IL253730A0/en unknown
- 2017-08-01 CL CL2017001956A patent/CL2017001956A1/en unknown
- 2017-08-03 PH PH12017550069A patent/PH12017550069A1/en unknown
- 2017-09-01 CO CONC2017/0009008A patent/CO2017009008A2/en unknown
-
2018
- 2018-06-12 HK HK18107636.5A patent/HK1248276A1/en unknown
-
2021
- 2021-07-02 US US17/367,242 patent/US20220143064A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20170359A (en) | 2017-11-24 |
| WO2016126995A1 (en) | 2016-08-11 |
| US20220143064A1 (en) | 2022-05-12 |
| CO2017009008A2 (en) | 2017-11-21 |
| EP3653712B1 (en) | 2022-11-30 |
| US10799523B2 (en) | 2020-10-13 |
| EP3653712A1 (en) | 2020-05-20 |
| ZA201705119B (en) | 2020-01-29 |
| KR20180016970A (en) | 2018-02-20 |
| US20160237427A1 (en) | 2016-08-18 |
| MX2017010066A (en) | 2017-11-01 |
| MA41586A (en) | 2017-12-13 |
| HK1248276A1 (en) | 2018-10-12 |
| DK3253875T3 (en) | 2020-04-14 |
| AU2016215155A1 (en) | 2017-08-17 |
| CA2975525A1 (en) | 2016-08-11 |
| CN107922946A (en) | 2018-04-17 |
| CL2017001956A1 (en) | 2018-06-01 |
| RU2017127609A (en) | 2019-03-04 |
| EP3253875A1 (en) | 2017-12-13 |
| EP3253875B1 (en) | 2020-01-08 |
| US20180161356A1 (en) | 2018-06-14 |
| PE20171766A1 (en) | 2017-12-21 |
| JP2018505676A (en) | 2018-03-01 |
| IL253730A0 (en) | 2017-09-28 |
| PH12017550069A1 (en) | 2018-02-05 |
| UY36550A (en) | 2016-08-31 |
| TW201641691A (en) | 2016-12-01 |
| BR112017016663A2 (en) | 2018-04-10 |
| US11077132B2 (en) | 2021-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1248276A1 (en) | Tau antisense oligomers and uses thereof | |
| GB201601312D0 (en) | Mems devices and processes | |
| HK1256419A1 (en) | Acetamide thienotriazolodiazepines and uses thereof | |
| HK1258246A1 (en) | Authentication methods and systems | |
| GB201503393D0 (en) | Polymers and uses thereof | |
| SG11201709032QA (en) | Contactor and contactor system | |
| HK1246303A1 (en) | Antisense antibacterial compounds and methods | |
| HK1247122A1 (en) | Combinations and uses thereof | |
| IL254241A0 (en) | Etv2 and uses thereof | |
| IL264473A (en) | Gpr156 variants and uses thereof | |
| HK1247220A1 (en) | Cyclic galanin-analogs and uses thereof | |
| PL3307080T3 (en) | Sweetener and use thereof | |
| IL258042A (en) | Tcr and uses thereof | |
| GB2545167B (en) | Cloches and use thereof | |
| GB201509031D0 (en) | Authentication methods and systems | |
| GB201509030D0 (en) | Authentication methods and systems |